COMMUNIQUÉS West-GlobeNewswire

Aravive to Host Key Opinion Leader Breakfast Symposium on AVB-S6-500 and the GAS6-AXL Pathway on February 5, 2019
29/01/2019
HOUSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) symposium focused on the GAS6-AXL pathway [...]
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
29/01/2019
Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators TORONTO, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, together with its majority shareholder FACIT, [...]
LHC Group Appoints National Healthcare Veteran Teri G. Fontenot to Board of Directors
29/01/2019
LAFAYETTE, La., Jan. 29, 2019 (GLOBE NEWSWIRE) -- LHC Group, Inc. (NASDAQ: LHCG) announced today that it has appointed Teri G. Fontenot to the Board of Directors, effective March 1, 2019. Ms. Fontenot, who will serve as [...]
Emerald Health Therapeutics’ Licensed Endo Product Line Gains Boost with Entry into Whole Foods Market Stores Across US
29/01/2019
Emerald Health Therapeutics and Emerald Health Naturals on track to launch endocannabinoid-supporting products in Canada VICTORIA, British Columbia, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“ [...]
Managers’ transactions
29/01/2019
Company Announcement No. 3/2019 January 29, 2019 For further information please contact: Martin Riise, Senior Director, Investor Relations, Tel: +45 5339 2250 Camilla Lercke, Head of Media Relations, Tel: +45 5339 2384 [...]
Nicox : Aval de la FDA américaine pour l'Investigational New Drug du NCX 4251 pour une étude de phase 2 dans la blépharite
29/01/2019
Communiqué de presse Nicox : Aval de la FDA américaine pour l'Investigational New Drug du NCX 4251 pour une étude de phase 2 dans la blépharite ................................................. 29 janvier 2019 - [...]
Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis
29/01/2019
Press Release Nicox Announces U.S. FDA Acceptance of Investigational New Drug Application for NCX 4251 Phase 2 Trial in Blepharitis ................................................ January 29 th , 2019 - release at 7:30 [...]
Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES
29/01/2019
PRESS RELEASE : REGULATED INFORMATION 29 January 2019, 07:00 CET Disclosure of Outstanding Voting Securities Mechelen, Belgium, 29 January 2019 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative [...]
INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME
29/01/2019
INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME Fast Track designation (FTD) is intended to expedite the development and regulatory review of IPH4102 for the [...]
INNATE PHARMA REÇOIT LE STATUT « FAST TRACK » DE LA FOOD AND DRUG ADMINISTRATION (FDA) POUR IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY EN RECHUTE OU RÉFRACTAIRE
29/01/2019
INNATE PHARMA REÇOIT LE STATUT « FAST TRACK » DE LA FOOD AND DRUG ADMINISTRATION (FDA) POUR IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY EN RECHUTE OU RÉFRACTAIRE Le statut « Fast Track » vise à accélérer [...]
Cancer Genetics, Inc. Announces Pricing of $3.5 Million Public Offering of Common Stock
29/01/2019
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today [...]
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering and Concurrent Private Placement
28/01/2019
HAMILTON, Bermuda, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa,” “we,” and “our”) announced today that it is commencing a public offering of 8,000,000 Class A common shares. [...]
IMV to Present at 2019 BIO CEO & Investor Conference
28/01/2019
DARTMOUTH, Nova Scotia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it will participate in the BIO CEO and Investor Conference [...]
Akorn Announces New Executive and Board Appointments
28/01/2019
LAKE FOREST, Ill., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), today announced that it has appointed a new executive team member and two new board members. Christopher C. Young joins Akorn as Executive [...]
Myriad to Announce Fiscal Second-Quarter 2019 Financial Results on February 5, 2019
28/01/2019
SALT LAKE CITY, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal second-quarter 2019 sales [...]
Corvus Pharmaceuticals Announces Appointment of New Member of Board of Directors and Hiring of Chief Medical Officer
28/01/2019
BURLINGAME, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted [...]
Cancer Genetics, Inc. Announces Proposed Public Offering of Common Stock
28/01/2019
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today [...]
Nextech’s EDGE 2019 Creates Hub for Collaboration and Education for Medical Specialty Professionals
28/01/2019
The fifth annual user conference will offer insights into upcoming industry trends and provide education and networking opportunities for healthcare providers in all roles TAMPA, Fla., Jan. 28, 2019 (GLOBE NEWSWIRE) -- [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 décembre 2018
28/01/2019
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au En application de l'article L. 233-8 II du code de commerce et de l'article 222-12-5 du règlement général de l'AMF, les sociétés dont [...]

Pages